Actively Recruiting
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-03-27
17
Participants Needed
1
Research Sites
364 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or programmed death ligand-1 (PD-L1). Immunotherapy is treatment that makes changes to the immune system to try to fight cancer. Immunotherapy treatments that block the activity of important parts of the immune system called PD-1 and PD-L1 are used to standardly treat many different types of cancer and can cause thyroid toxicity in certain people. In this study the treatment for your cancer is not research treatment but standard of care determined by your oncologist. Blood will be drawn before starting treatment to determine the amount of Vitamin D and also to assess thyroid function. Also questionnaires will be completed before starting treatment and while on treatment to assess symptoms you are experiencing.
CONDITIONS
Official Title
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Malignancy requiring PD-1 or PD-L1 inhibitor as the only immunotherapy for next treatment
- Willingness to complete symptom questionnaires
- Willingness to allow blood draws
- Ability to provide informed consent
- Age over 18 years old
You will not qualify if you...
- History of clinical or subclinical hyperthyroidism or hypothyroidism
- Hemoglobin level less than 9
- Inability to attend all study visits
- Currently taking vitamin D supplements for vitamin D deficiency (multivitamin use allowed)
- Pregnant or lactating
- History of hypophysitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center
New York, New York, United States, 10029
Actively Recruiting
Research Team
P
Philip Friedlander, MD PhD
CONTACT
E
Emily Gallagher, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here